Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6 ; Фармакотерапия гигантоклеточного артериита и ревматической полимиалгии: перспективы применения моноклональных антител к интерлейкину 6

Συγγραφείς: Evgeny L. Nasonov, Azamat M. Satybaldyev, Elvira N. Otteva, Tatiana V. Beketova, Andrey A. Baranov, Е. Л. Насонов, А. М. Сатыбалдыев, Э. Н. Оттева, Т. В. Бекетова, А. А. Баранов

Πηγή: Rheumatology Science and Practice; Vol 62, No 4 (2024); 348–364 ; Научно-практическая ревматология; Vol 62, No 4 (2024); 348–364 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: тоцилизумаб, polymyalgia rheumatica, interleukin 6, interleukin 6 inhibitors, tocilizumab, ревматическая полимиалгия, интерлейкин 6, ингибиторы интерлейкина 6

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3600/2384; Pugh D, Karabayas M, Basu N, Cid MC, Goel R, Goodyear CS, et al. Large-vessel vasculitis. Nat Rev Dis Primers. 2022;7(1):93. doi:10.1038/s41572-021-00327-5; Buttgereit F, Matteson EL, Dejaco C. Polymyalgia rheumatica and giant cell arteritis. JAMA. 2020;324(10):993-994. doi:10.1001/ jama.2020.10155; Сатыбалдыев АМ, Демидова НВ, Савушкина НМ, Гордеев АВ. Ревматическая полимиалгия. Научно-практическая ревматология. 2018;56(2):215-227. doi:10.14412/1995-4484-2018-215-227; Сатыбалдыев АМ. Эволюция диагностики ревматической полимиалгии. Научно-практическая ревматология. 2019;57(6):693-698. doi:10.14412/1995-4484-2019-693-698; Sharma A, Mohammad AJ, Turesson C. Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review. Semin Arthritis Rheum. 2020;50(5):1040-1048. doi:10.1016/j.semarthrit.2020.07.005; Hemmig AK, Gozzoli D, Werlen L, Ewald H, Aschwanden M, Blockmans D, et al. Subclinical giant cell arteritis in new onset polymyalgia rheumatica: A systematic review and meta-analysis of individual patient data. Semin Arthritis Rheum. 2022;55:152017. doi:10.1016/j.semarthrit.2022.152017; Salvarani C, Padoan R, Iorio L, Tomelleri A, Terrier B, Muratore F, et al. Subclinical giant cell arteritis in polymyalgia rheumatica: Concurrent conditions or a common spectrum of inflammatory diseases? Autoimmun Rev. 2024;23(1):103415. doi:10.1016/j.autrev.2023.103415; Owen CE, Poon AMT, Liu B, Liew DFL, Yap LP, Yang V, et al. Characterising polymyalgia rheumatica on whole-body 18F-FDG PET/CT: An atlas. Rheumatol Adv Pract. 2024;8(1):rkae003. doi:10.1093/rap/rkae003; Tomelleri A, van der Geest KSM, Khurshid MA, Sebastian A, Coath F, Robbins D, et al. Disease stratification in GCA and PMR: State of the art and future perspectives. Nat Rev Rheumatol. 2023;19(7):446-459. doi:10.1038/s41584-023-00976-8; Schäfer VS, Brossart P, Warrington KJ, Kurts C, Sendtner GW, Aden CA. The role of autoimmunity and autoinflammation in giant cell arteritis: A systematic literature review. Autoimmun Rev. 2023;22(6):103328. doi:10.1016/j.autrev.2023.103328; Greigert H, Genet C, Ramon A, Bonnotte B, Samson M. New insights into the pathogenesis of giant cell arteritis: Mechanisms involved in maintaining vascular inflammation. J Clin Med. 2022;11(10):2905. doi:10.3390/jcm11102905; Akiyama M, Ohtsuki S, Berry GJ, Liang DH, Goronzy JJ, Weyand CM. Innate and adaptive immunity in giant cell arteritis. Front Immunol. 2021;11:621098. doi:10.3389/fimmu.2020.621098; Weyand CM, Goronzy JJ. Immunology of giant cell arteritis. Circ Res. 2023;132(2):238-250. doi:10.1161/CIRCRESAHA.122.322128; Mackie SL, Owen CE, Buchanan RRC, McGonagle D. A shared basis for overlapping immunopathologies in giant cell arteritis and polymyalgia rheumatica. Lancet Rheumatol. 2021;3(12):e826-e829. doi:10.1016/S2665-9913(21)00361-1; Mulhearn B, Ellis J, Skeoch S, Pauling J, Tansley S. Incidence of giant cell arteritis is associated with COVID-19 prevalence: A population-level retrospective study. Heliyon. 2023;9(7):e17899. doi:10.1016/j.heliyon.2023.e17899; Luther R, Skeoch S, Pauling JD, Curd C, Woodgate F, Tansley S. Increased number of cases of giant cell arteritis and higher rates of ophthalmic involvement during the era of COVID-19. Rheumatol Adv Pract. 2020;4(2):rkaa067. doi:10.1093/rap/rkaa067; Aryal B, Kadakia N, Baniya A, Chowdhury T, Adhikari S, Gousy N. Overlapping symptoms of COVID-19 and giant cell arteritis: The need for a higher degree of suspicion for diagnostic differentiation. Cureus. 2022;14(6):e25660. doi:10.7759/cureus.25660; McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019;50(4):892-906. doi:10.1016/j.immuni.2019.03.021; Насонов ЕЛ. Новые возможности фармакотерапии иммуновоспалительных ревматических заболеваний: фокус на ингибиторы интерлейкина 17. Научно-практическая ревматология. 2017;55(1):68-86. doi:10.14412/1995-4484-2017-68-86; Zeisbrich M, Thiel J, Venhoff N. The IL-17 pathway as a target in giant cell arteritis. Front Immunol. 2024;14:1199059. doi:10.3389/fimmu.2023.1199059; Robinette ML, Weeks LD, Kramer RJ, Agrawal M, Gibson CJ, Yu Z, et al. Association of somatic TET2 mutations with giant cell arteritis. Arthritis Rheumatol. 2024;76(3):438-443. doi:10.1002/art.42738; Gutierrez-Rodrigues F, Wells KV, Jones AI, Hironaka D, Rankin C, Gadina M, et al. Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu’s arteritis, ANCAassociated vasculitis and giant cell arteritis. Ann Rheum Dis. 2024;83(4):508-517. doi:10.1136/ard-2023-224933; Papo M, Friedrich C, Delaval L, Boysson H, Viallard JF, Bachmeyer C, et al.; French Vasculitis Study Group. Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis: A case-control and exploratory study. Rheumatology (Oxford). 2022;61(2):775-780. doi:10.1093/rheumatology/keab337; Dejaco C, Kerschbaumer A, Aletaha D, Bond M, Hysa E, Camellino D, et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2024;83(1):48-57. doi:10.1136/ard-2022-223429; Hysa E, Bond M, Ehlers L, Camellino D, Falzon L, Dejaco C, et al. Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: A systematic literature review. Rheumatology (Oxford). 2024;63(2):285-297. doi:10.1093/rheumatology/kead471; Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19-30. doi:10.1136/annrheumdis-2019-215672; Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al.; European League Against Rheumatism; American College of Rheumatology. 2015 recommendations for the management of polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74(10):1799-1807. doi:10.1136/ annrheumdis-2015-207492; Бекетова ТВ, Попов ИЮ, Зеленов ВА. Обзор рекомендаций American College of Rheumatology/Vasculitis Foundation по лечению системных васкулитов крупных сосудов (гигантоклеточного артериита и артериита Такаясу). Научно-практическая ревматология. 2022;60(2):165-173. doi:10.47360/1995-4484-2022-165-173; Monti S, Águeda AF, Luqmani RA, Buttgereit F, Cid M, Dejaco C, et al. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: Focus on giant cell arteritis. RMD Open. 2019;5(2):e001003. doi:10.1136/rmdopen-2019-001003; Scolnik M, Brance ML, Fernández-Ávila DG, Inoue Sato E, de Souza AWS, Magri SJ, et al.; Pan American League of Associations for Rheumatology (PANLAR). Pan American League of Associations for Rheumatology guidelines for the treatment of giant cell arteritis. Lancet Rheumatol. 2022;4(12):e864-e872. doi:10.1016/S2665-9913(22)00260-0; Toyoda T, Armitstead Z, Bhide S, Engamba S, Henderson E, Jones C, et al. Treatment of polymyalgia rheumatica: British Society for Rheumatology guideline scope. Rheumatol Adv Pract. 2024;8(1):rkae002. doi:10.1093/rap/rkae002; Haaversen AB, Brekke LK, Bakland G, Rødevand E, Myklebust G, Diamantopoulos AP. Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with giant cell arteritis. Front Med (Lausanne). 2023;9:1082604. doi:10.3389/fmed.2022.1082604; Turesson C, Börjesson O, Larsson K, Mohammad AJ, Knight A. Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis. Scand J Rheumatol. 2019;48(4):259-265. doi:10.1080/03009742.2019.1571223; Ughi N, Padoan R, Crotti C, Sciascia S, Carrara G, Zanetti A, et al. The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis. Reumatismo. 2022;73(4). doi:10.4081/reumatismo.2021.1470; Matteson EL, Buttgereit F, Dejaco C, Dasgupta B. Glucocorticoids for management of polymyalgia rheumatica and giant cell arteritis. Rheum Dis Clin North Am. 2016;42(1):75-90viii. doi:10.1016/j.rdc.2015.08.009; Strehl C, Ehlers L, Gaber T, Buttgereit F. Glucocorticoids-allrounders tackling the versatile players of the immune system. Front Immunol. 2019;10:1744. doi:10.3389/fimmu.2019.01744; Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation. 2010;121(7):906-915. doi:10.1161/CIRCULATIONAHA.109.872903; Estupiñán-Moreno E, Ortiz-Fernández L, Li T, Hernández-Rodríguez J, Ciudad L, Andrés-León E, et al. Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids. Ann Rheum Dis. 2022;81(9):1290-1300. doi:10.1136/annrheumdis-2022-222156; Mainbourg S, Addario A, Samson M, Puéchal X, François M, Durupt S, et al. Prevalence of giant cell arteritis relapse in patients treated with glucocorticoids: A meta-analysis. Arthritis Care Res (Hoboken). 2020;72(6):838-849. doi:10.1002/acr.23901; Floris A, Piga M, Chessa E, Congia M, Erre GL, Angioni MM, et al. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: A systematic literature review and meta-analysis. Clin Rheumatol. 2022;41(1):19-31. doi:10.1007/s10067-021-05819-z; Moreel L, Betrains A, Molenberghs G, Blockmans D, Vanderschueren S. Duration of treatment with glucocorticoids in giant cell arteritis: A systematic review and meta-analysis. J Clin Rheumatol. 2023;29(6):291-297. doi:10.1097/RHU.0000000000001897; Dumont A, Parienti JJ, Delmas C, Boutemy J, Maigné G, Martin Silva N, et al. Factors associated with relapse and dependence on glucocorticoids in giant cell arteritis. J Rheumatol. 2020;47(1):108-116. doi:10.3899/jrheum.181127; Tsalapaki C, Lazarini A, Argyriou E, Dania V, Boki K, Evangelatos G, et al. Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritis. Rheumatol Int. 2024;44(4):603-610. doi:10.1007/s00296-023-05527-8; Sugihara T, Hasegawa H, Uchida HA, Yoshifuji H, Watanabe Y, Amiya E, et al.; Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS). Associated factors of poor treatment outcomes in patients with giant cell arteritis: Clinical implication of large vessel lesions. Arthritis Res Ther. 2020;22(1):72. doi:10.1186/s13075-020-02171-6; de Mornac D, Espitia O Néel A, Connault J, Masseau A, Espitia-Thibault A, et al. Large-vessel involvement is predictive of multiple relapses in giant cell arteritis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211009029. doi:10.1177/1759720X211009029; Esen I, Arends S, Dalsgaard Nielsen B, Therkildsen P, Hansen I, van ‘t Ende A, et al. Metabolic features and glucocorticoidinduced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort. RMD Open. 2023;9(1):e002640. doi:10.1136/rmdopen-2022-002640; Perrineau S, Ghesquière T, Charles P, Paule R, Samson M, Gayraud M, et al.; French Vasculitis Study Group (FVSG). A French cohort of patients with giant cell arteritis: Glucocorticoid treatment and its associated side effects. Clin Exp Rheumatol. 2021; 129(2 Suppl 39):155-160. doi:10.55563/clinexprheumatol/0nd4kk; Bond M, Tomelleri A, Buttgereit F, Matteson EL, Dejaco C. Looking ahead: Giant-cell arteritis in 10 years time. Ther Adv Musculoskelet Dis. 2022;14:1759720X221096366. doi:10.1177/1759720X221096366; Ricordi C, Pipitone N, Marvisi C, Muratore F, Salvarani C. Steroid-sparing agents in polymyalgia rheumatica: How will they fit into the treatment paradigm? Expert Rev Clin Immunol. 2023;19(10):1195-1203. doi:10.1080/1744666X.2023.2240519; Nepal D, Putman M, Unizony S. Giant cell arteritis and polymyalgia rheumatica: Treatment approaches and new targets. Rheum Dis Clin North Am. 2023;49(3):505-521. doi:10.1016/j.rdc.2023.03.005; Sandovici M, van der Geest N, van Sleen Y, Brouwer E. Need and value of targeted immunosuppressive therapy in giant cell arteritis. RMD Open. 2022;8(1):e001652. doi:10.1136/rmdopen-2021-001652; Watanabe R, Hashimoto M. Perspectives of JAK inhibitors for large vessel vasculitis. Front Immunol. 2022;13:881705. doi:10.3389/fimmu.2022.881705; Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: Achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(6):590-599 (In Russ.)]. doi:10.14412/1995-4484-2017-590-599; Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335-345. doi:10.1038/s41584-020-0419-z; Emilie D, Liozon E, Crevon MC, Lavignac C, Portier A, Liozon F, et al. Production of interleukin 6 by granulomas of giant cell arteritis. Hum Immunol. 1994;39(1):17-24. doi:10.1016/0198-8859(94)90096-5; Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: Interleukin-6 as a biologic marker of disease activity. Arthritis Rheum. 2000;43(5):1041-1048. doi:10.1002/1529-0131(200005)43:53.0.CO;2-7; García-Martínez A, Hernández-Rodríguez J, Espígol-Frigolé G, Prieto-González S, Butjosa M, Segarra M, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term follow-up of patients with giant cell arteritis. Arthritis Care Res (Hoboken). 2010;62(6):835-841. doi:10.1002/acr.20043; Carvajal Alegria G, Nicolas M, van Sleen Y. Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: Is it possible to replace acute-phase reactants? Front Immunol. 2023;14:1202160. doi:10.3389/fimmu.2023.1202160; Tombetti E, Hysa E, Mason JC, Cimmino MA, Camellino D. Blood biomarkers for monitoring and prognosis of large vessel vasculitides. Curr Rheumatol Rep. 2021;23(3):17. doi:10.1007/s11926-021-00980-5; Visvanathan S, Rahman MU, Hoffman GS, Xu S, García-Martínez A, Segarra M, et al. Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis – A prospective longitudinal study. Rheumatology (Oxford). 2011;50(11):2061-2070. doi:10.1093/rheumatology/ker163; Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M, García-Martínez A, Esteban MJ, et al. Tissue production of proinflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford). 2004;43(3):294-301. doi:10.1093/rheumatology/keh058; Miyabe C, Miyabe Y, Strle K, Kim ND, Stone JH, Luster AD, et al. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Ann Rheum Dis. 2017;76(5):898-905. doi:10.1136/annrheumdis-2016-210070; Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: Vascular intrinsic and extrinsic factors and potential role of IL-6. Nat Rev Cardiol. 2021;18(1):58-68. doi:10.1038/s41569-020-0431-7; Veroutis D, Argyropoulou OD, Goules AV, Kambas K, Palamidas DA, Evangelou K, et al. Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways. Ann Rheum Dis. 2024;83(3):342350. doi:10.1136/ard-2023-224467; Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ Res. 2021;128(11):1728-1746. doi:10.1161/CIRCRESAHA.121.319077; Ghanemi A, St-Amand J. Interleukin-6 as a “metabolic hormone”. Cytokine. 2018;112:132-136. doi:10.1016/j.cyto.2018.06.034; Clifford AH. Cardiovascular disease in large vessel vasculitis: Risks, controversies, and management strategies. Rheum Dis Clin North Am. 2023;49(1):81-96. doi:10.1016/j.rdc.2022.08.004; de Boysson H, Aouba A. An updated review of cardiovascular events giant cell arteritis. J Clin Med. 2022;11(4):1005. doi:10.3390/jcm11041005; Kastrati K, Aletaha D, Burmester GR, Chwala E, Dejaco C, Dougados M, et al. A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD Open. 2022;8(2):e002359. doi:10.1136/rmdopen-2022-002359; Nasonov E, Feist E. Interleukin 6 inhibition in rheumatoid arthritis: Highlight on olokizumab. Touch Reviews in RMD. 2023;2(1):17-27. doi:10.17925/RMD.2023.2.1.17; Loricera J, Blanco R, Hernández JL, Castañeda S, Mera A, Pérez-Pampín E, et al. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. Semin Arthritis Rheum. 2015;44(6):717-723. doi:10.1016/j.semarthrit.2014.12.005; Régent A, Redeker S, Deroux A, Kieffer P, Ly KH, Dougados M, et al.; French Vasculitis Group, the Groupe Francais pour l’Etude de l’Artérite à Cellules Géantes, and the Club Rhumatismes et Inflammation. Tocilizumab in giant cell arteritis: A multicenter retrospective study of 34 patients. J Rheumatol. 2016;43(8):15471552. doi:10.3899/jrheum.151252; Samson M, Devilliers H, Ly KH, Maurier F, Bienvenu B, Terrier B, et al. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of giant cell arteritis: A prospective study. Eur J Intern Med. 2018;57:96-104. doi:10.1016/j.ejim.2018.06.008; Adler S, Reichenbach S, Gloor A, Yerly D, Cullmann JL, Villiger PM. Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology (Oxford). 2019;58(9):1639-1643. doi:10.1093/rheumatology/kez091; Nannini C, Niccoli L, Sestini S, Laghai I, Coppola A, Cantini F. Remission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis: An open-label, 18-month, prospective, pilot study. Ann Rheum Dis. 2019;78(10):1444-1446. doi:10.1136/annrheumdis-2019-215585; Calderón-Goercke M, Loricera J, Aldasoro V, Castañeda S, Villa I, Humbría A, et al. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. Semin Arthritis Rheum. 2019;49(1):126-135. doi:10.1016/j.semarthrit.2019.01.003; Amsler J, Kysela I, Tappeiner C, Seitz L, Christ L, Scholz G, et al. Vision loss in patients with giant cell arteritis treated with tocilizumab. Arthritis Res Ther. 2021;23(1):92. doi:10.1186/s13075-021-02480-4; Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10031):1921-7. doi:10.1016/S0140-6736(16)00560-2; Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317-328. doi:10.1056/NEJ-Moa1613849; Tuckwell K, Collinson N, Dimonaco S, Klearman M, Blockmans D, Brouwer E, et al.; GiACTA Investigators. Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. Semin Arthritis Rheum. 2017;46(5):657-664. doi:10.1016/j.semarthrit.2016.11.002; Unizony S, Matza MA, Jarvie A, O’Dea D, Fernandes AD, Stone JH. Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: A single-arm, open-label, proof-of-concept study. Lancet Rheumatol. 2023;5(12):e736-e742. doi:10.1016/S2665-9913(23)00265-5; Clément J, Duffau P, Constans J, Schaeverbeke T, Viallard JF, Barcat D, et al. Real-world risk of relapse of giant cell arteritis treated with tocilizumab: A retrospective analysis of 43 patients. J Rheumatol. 2021;48(9):1435-1441. doi:10.3899/jrheum.200952; Matza MA, Dagincourt N, Mohan SV, Pavlov A, Han J, Stone JH, et al. Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis. RMD Open. 2023;9(2):e002923. doi:10.1136/rmdopen-2022-002923; Loricera J, Castañeda S, Moriano C, Narváez J, Aldasoro V, Maiz O, et al. Tocilizumab in visual involvement of giant cell arteritis: A multicenter study of 471 patients. Ther Adv Musculoskelet Dis. 2022;14:1759720X221113747; Unizony S, McCulley TJ, Spiera R, Pei J, Sidiropoulos PN, Best JH, et al. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: Decreased incidence of new visual manifestations. Arthritis Res Ther. 2021;23(1):8. doi:10.1186/s13075-020-02377-8; Harigai M, Miyamae T, Hashimoto H, Umetsu K, Yamashita K, Nakaoka Y. A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan. Mod Rheumatol. 2023 Jul 31:road074. doi:10.1093/mr/road074; Muratore F, Marvisi C, Cassone G, Boiardi L, Mancuso P, Besutti G, et al. Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: The role of imaging in a prospective observational study. Rheumatology (Oxford). 2024;63(1):64-71. doi:10.1093/rheumatology/kead215; Quinn KA, Dashora H, Novakovich E, Ahlman MA, Grayson PC. Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis. Rheumatology (Oxford). 2021;60(9):4384-4389. doi:10.1093/rheumatology/keaa894; Samec MJ, Rakholiya J, Langenfeld H, Crowson CS, Abril A, Wang B, et al. Relapse risk and safety of long-term tocilizumab use among patients with giant cell arteritis: A single-enterprise cohort study. J Rheumatol. 2023;50(10):1310-1317. doi:10.3899/jrheum.2022-1214; Christ L, Seitz L, Scholz G, Sarbu AC, Amsler J, Bütikofer L, et al. Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: A single-arm, open-label, proof-of-concept study. Lancet Rheumatol. 2021;3(9):e619-e626. doi:10.1016/S2665-9913(21)00152-1; Tomelleri A, Campochiaro C, Farina N, Mariotti L, Baldissera E, Grayson PC, et al. Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study. Semin Arthritis Rheum. 2023;59:152174. doi:10.1016/j.semarthrit.2023.152174; Saito S, Okuyama A, Okada Y, Shibata A, Sakai R, Kurasawa T, et al. Tocilizumab monotherapy for large vessel vasculitis: Results of 104-week treatment of a prospective, single-centre, open study. Rheumatology (Oxford). 2020;59(7):1617-1621. doi:10.1093/rheumatology/kez511; Calderón-Goercke M, Castañeda S, Aldasoro V, Villa I, Moriano C, Romero-Yuste S, et al.; Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group. Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients. Semin Arthritis Rheum. 2021;51(2):387-394. doi:10.1016/j.semarthrit.2021.01.006; Seitz L, Christ L, Lötscher F, Scholz G, Sarbu AC, Bütikofer L, et al. Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis. Rheumatology (Oxford). 2021;60(11):5052-5059. doi:10.1093/rheumatology/keab484; Grazzini S, Conticini E, Falsetti P, D’Alessandro M, Sota J, Terribili R, et al. Tocilizumab vs methotrexate in a cohort of patients affected by active GCA: A comparative clinical and ultrasonographic study. Biologics. 2023;17:151-160. doi:10.2147/BTT.S431818; Calderón-Goercke M, Loricera J, Moriano C, Castañeda S, Narváez J, Aldasoro V, et al.; Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients. Clin Exp Rheumatol. 2023;41(4):829-836. doi:10.55563/clinexprheumatol/oqs8u9; Izumi K, Murata O, Higashida-Konishi M, Kaneko Y, Oshima H, Takeuchi T. Steroid-sparing effect of tocilizumab and methotrexate in patients with polymyalgia rheumatica: A retrospective cohort study. J Clin Med. 2021;10(13):2948. doi:10.3390/jcm10132948; Sánchez-Bilbao L, Loricera J, Castañeda S, Moriano C, Narváez F, Aldasoro V, et al. Intravenous versus subcutaneous tocilizumab in a series of 471 patients with giant cell arteritis. Arthritis Rheumatol. 2022; 74(Suppl 9). URL: https://acrabstracts.org/abstract/intravenous-versus-subcutaneous-tocilizumab-in-a-series-of-471-patients-with-giant-cell-arteritis (Accessed: 14th April, 2024).; Sanchez-Bilbao L, Loricera J, Aldasoro V.; on behalf of Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group. Tocilizumab in cranial and extracranial refractory giant cell arteritis: A multicenter study of 312 cases. Ann Rheum. Dis. 2021;80:34-35.; Beketova TV, Otteva EN, Nasonov EL. Tocilizumab for the treatment of giant cell arteritisand polymyalgia rheumatica in patients with serious comorbidities: experience of two Russian centers. Clinical Pharmacology and Therapy. 2020;29(1):31-35 (In Russ.)]. doi:10.32756/0869-5490-2020-1-31-35; Schmidt WA, Dasgupta B, Luqmani R, Unizony SH, Blockmans D, Lai Z, et al. A multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of sirukumab in the treatment of giant cell arteritis. Rheumatol Ther. 2020;7(4):793-810. doi:10.1007/s40744-020-00227-2; Stone JH, Spotswood H, Unizony SH, Aringer M, Blockmans D, Brouwer E, et al. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatology (Oxford). 2022;61(7):2915-2922. doi:10.1093/rheumatology/keab780; Stone JH, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, et al.; GiACTA investigators. Long-term effect of tocilizumab in patients with giant cell arteritis: Open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. Lancet Rheumatol. 2021;3(5):e328-e336. doi:10.1016/S2665-9913(21)00038-2; Strand V, Dimonaco S Tuckwell K, Klearman M, Collinson N, Stone JH. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial. Arthritis Res Ther. 2019;21(1):64. doi:10.1186/s13075-019-1837-7; Spiera R, Unizony SH, Bao M, Luder Y, Han J, Pavlov A, et al. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. Semin Arthritis Rheum. 2021;51(2):469-476. doi:10.1016/j.semarthrit.2021.03.006; Castañeda S, Prieto-Peña D, Vicente-Rabaneda EF, TrigueroMartínez A, Roy-Vallejo E, Atienza-Mateo B, et al. Advances in the treatment of giant cell arteritis. J Clin Med. 2022;11(6):1588. doi:10.3390/jcm11061588; Stretton B, Tan Y, Hassall M, Simon S. The role of tocilizumab in glucocorticoid resistant giant cell arteritis: A case series and literature review. J Neuroophthalmol. 2023;43(1):91-95. doi:10.1097/WNO.0000000000001645; Svasti-Salee CR, Mollan SP, Morgan AW, Quick V. Rapid visual recovery following intravenous tocilizumab in glucocorticoid resistant refractory giant cell arteritis. BMJ Case Rep. 2019;12(10):e229236. doi:10.1136/bcr-2019-229236; Khanna RK, Hage R, Lecler A, Sene T, Vignal-Clermont C, Clavel-Refregiers G. Giant cell arteritis with ocular involvement successfully treated with tocilizumab and very short-course glucocorticoids: A case report. J Fr Ophtalmol. 2021;44(4):481-484. doi:10.1016/j.jfo.2020.08.028; Sebastian A, Kayani A, Prieto-Pena D, Tomelleri A, Whitlock M, Mo J, et al. Efficacy and safety of tocilizumab in giant cell arteritis: A single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool. RMD Open. 2020;6(3):e001417. doi:10.1136/rmdopen-2020-001417; Schönau V, Roth J, Tascilar K, Corte G, Manger B, Rech J, et al. Resolution of vascular inflammation in patients with new-onset giant cell arteritis: Data from the RIGA study. Rheumatology (Oxford). 2021;60(8):3851-3861. doi:10.1093/rheumatology/ keab332; Prieto Peña D, Martínez-Rodríguez I, Atienza-Mateo B, Calderón-Goercke M, Banzo I, González-Vela MC, et al. Evidence for uncoupling of clinical and 18-FDG activity of PET/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis. Clin Exp Rheumatol. 2021;39(Suppl 129(2)):6975. doi:10.55563/clinexprheumatol/mjm8fr; Reichenbach S, Adler S, Bonel H, Cullmann JL, Kuchen S, Bütikofer L, et al. Magnetic resonance angiography in giant cell arteritis: Results of a randomized controlled trial of tocilizumab in giant cell arteritis. Rheumatology (Oxford). 2018;57(6):982-986. doi:10.1093/rheumatology/key015.; Hemmig AK, Rottenburger C, Baruti L, Mensch N, Aschwanden M, Kyburz D, et al. Imaging to predict early relapses after treatment discontinuation in patients with large vessel giant cell arteritis – A cohort study. Semin Arthritis Rheum. 2024;66:152425. doi:10.1016/j.semarthrit.2024.152425; Nepal D, Sattui S, Wallace Z, Putman M. Risk of gastrointestinal perforation among patients with giant cell arteritis who received tocilizumab. Arthritis Rheumatol. 2023; 75(Suppl 9). URL: https://acrabstracts.org/abstract/risk-of-gastrointestinal-perforation-among-patients-with-giant-cell-arteritis-who-received-tocilizumab (Accessed: 17th April, 2024).; Unizony SH, Bao M, Han J, Luder Y, Pavlov A, Stone JH. Treatment failure in giant cell arteritis. Ann Rheum Dis. 2021;80(11):1467-1474. doi:10.1136/annrheumdis-2021-220347; Antonio AA, Santos RN, Abariga SA. Tocilizumab for giant cell arteritis. Cochrane Database Syst Rev. 2021;8(8):CD013484. doi:10.1002/14651858.CD013484.pub2; Patel NJ, Tozzo V, Higgins JM, Stone JH. The effects of daily prednisone and tocilizumab on hemoglobin A1c during the treatment of giant cell arteritis. Arthritis Rheumatol. 2023;75(4):586594. doi:10.1002/art.42405; Buttgereit F, Palmowski A, Esen I, Brouwer E. Tocilizumab in giant cell arteritis: Better understanding the benefits. Arthritis Rheumatol. 2023;75(4):489-492. doi:10.1002/art.42414; Schmidt WA, Dasgupta B, Sloane J, Giannelou A, Xu Y, Unizony SH, et al. A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis. Arthritis Res Ther. 2023;25(1):199. doi:10.1186/s13075-023-03177-6; Macchioni P, Boiardi L, Catanoso M, Pulsatelli L, Pipitone N, Meliconi R, et al. Tocilizumab for polymyalgia rheumatica: Report of two cases and review of the literature. Semin Arthritis Rheum. 2013;43(1):113-118. doi:10.1016/j.semarthrit.2013.01.003; Lally L, Forbess L, Hatzis C, Spiera R. Brief report: A prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol. 2016;68(10):2550-2554. doi:10.1002/art.39740; Ashraf FA, Anjum S, Hussaini A, Fraser A. Refractory PMR with aortitis: Life-saving treatment with anti-IL6 monoclonal antibody (tocilizumab) and surgical reconstruction of the ascending aorta. BMJ Case Rep. 2013;2013:bcr2013009523. doi:10.1136/bcr-2013-009523; Izumi K, Kuda H, Ushikubo M, Kuwana M, Takeuchi T, Oshima H. Tocilizumab is effective against polymyalgia rheumatica: Experience in 13 intractable cases. RMD Open. 2015;1(1):e000162. doi:10.1136/rmdopen-2015-000162; Mori S, Koga Y. Glucocorticoid-resistant polymyalgia rheumatica: Pretreatment characteristics and tocilizumab therapy. Clin Rheumatol. 2016;35(5):1367-1375. doi:10.1007/s10067-014-2650-y; Devauchelle-Pensec V, Berthelot JM, Cornec D, Renaudineau Y, Marhadour T, Jousse-Joulin S, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: A prospective longitudinal study. Ann Rheum Dis. 2016;75(8):1506-1510. doi:10.1136/annrheumdis-2015-208742; Bonelli M, Radner H, Kerschbaumer A, Mrak D, Durechova M, Stieger J, et al. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): A phase 2/3 randomised controlled trial. Ann Rheum Dis. 2022;81(6):838-844. doi:10.1136/ annrheumdis-2021-221126; Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, Richez C, Truchetet ME, Wendling D, et al. Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: A randomized clinical trial. JAMA. 2022;328(11):1053-1062. doi:10.1001/jama.2022.15459; Chino K, Kondo T, Sakai R, Saito S, Okada Y, Shibata A, et al. Tocilizumab monotherapy for polymyalgia rheumatica: A prospective, single-center, open-label study. Int J Rheum Dis. 2019;22(12):2151-2157. doi:10.1111/1756-185X.13723; Assaraf M, Chevet B, Wendling D, Philippe P, Cailliau E, Roux C, et al. Efficacy and management of tocilizumab in polymyalgia rheumatica: Results of a multicenter retrospective observational study. Rheumatology (Oxford). 2023 Aug 21:kead426. doi:10.1093/rheumatology/kead426; Curtis J, Ford K, Fiore S, Isaman D, Araujo L, Petruski-Ivleva N, et al. Effectiveness of interleukin-6 receptor inhibitors for polymyalgia rheumatica. Arthritis Rheumatol. 2022;74(Suppl 9). URL: https://acrabstracts.org/abstract/effectiveness-of-interleukin-6-receptor-inhibitors-for-polymyalgia-rheumatica (Accessed: 3rd April, 2024).; Spiera RF, Unizony S, Warrington KJ, Sloane J, Giannelou A, Nivens MC, et al.; SAPHYR Investigators. Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper. N Engl J Med. 2023;389(14):1263-1272. doi:10.1056/NEJMoa2303452; Akiyama M, Kaneko Y, Takeuchi T. Tocilizumab in isolated polymyalgia rheumatica: A systematic literature review. Semin Arthritis Rheum. 2020;50(3):521-525. doi:10.1016/j.semarthrit.2019.12.005; Farinango M, Ansary A, Dakka A, Nazir Z, Shamim H, Jean M, et al. Is tocilizumab effective and safe in polymyalgia rheumatica and giant-cell arteritis with polymyalgia rheumatica? Cureus. 2022;14(8):e27606. doi:10.7759/cureus.27606; Dasgupta B, Unizony S, Warrington KJ, Lazar JS, Giannelou A, Nivens MC, et al. Sarilumab in patients with relapsing polymyalgia rheumatica: A phase 3, multicenter, randomized, double blind, placebo controlled trial (SAPHYR). Ann Rheum Dis. 2022;81:210-211.; De Miguel E, Karalilova R, Macchioni P, Ponte C, Conticini E, Cowley S, et al. Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica. Ann Rheum Dis. 2024;83(3):335-341. doi:10.1136/ard-2023-224768; Aletaha D, Kerschbaumer A, Kastrati K, Dejaco C, Dougados M, McInnes IB, et al. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: An update. Ann Rheum Dis. 2023;82(6):773-787. doi:10.1136/ard-2022-222784; Hanberg JS, Miloslavsky EM. Steroid sparing in vasculitis: Myth or reality? Best Pract Res Clin Rheumatol. 2023;37(1):101843. doi:10.1016/j.berh.2023.101843; Oiwa H, Suga T, Hosokawa Y, Araki K. Glucocorticoid-free remission in patients with SLE in the era of biologics: Immune complex disease is likely to benefit from current medications. Lupus. 2024;33(5):502-510. doi:10.1177/09612033241238055; Burmester GR, Buttgereit F, Bernasconi C, Álvaro-Gracia JM, Castro N, Dougados M, et al.; SEMIRA collaborators. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): A double-blind, multicentre, randomised controlled trial. Lancet. 2020;396(10246):267-276. doi:10.1016/S0140-6736(20)30636-X; Boers M, Hartman L, Opris-Belinski D, Bos R, Kok MR, Da Silva JA, et al.; GLORIA Trial consortium. Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: The pragmatic randomised, double-blind placebo-controlled GLORIA trial. Ann Rheum Dis. 2022;81(7):925-936. doi:10.1136/annrheumdis-2021-221957; Plocque A, Mitri C, Lefèvre C, Tabary O, Touqui L, Philippart F. Should we interfere with the interleukin-6 receptor during COVID-19: What do we know so far? Drugs. 2023;83(1):1-36. doi:10.1007/s40265-022-01803-2; Northcott M, Gearing LJ, Nim HT, Nataraja C, Hertzog P, Jones SA, et al. Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: A cross-sectional and in-vitro study. Lancet Rheumatol. 2021;3(5):e357-e370. doi:10.1016/S2665-9913(21)00006-0; Vieira M, Régnier P, Maciejewski-Duval A, Le Joncour A, Darasse-Jèze G, Rosenzwajg M, et al. Interferon signature in giant cell arteritis aortitis. J Autoimmun. 2022;127:102796. doi:10.1016/j.jaut.2022.102796; Van Nieuwland M, Esen I, Reitsema RD, Abdulahad WH, van Sleen Y, Jiemy WF, et al. Evidence for increased interferon type I activity in CD8+ T cells in giant cell arteritis patients. Front Immunol. 2023;14:1197293. doi:10.3389/fimmu.2023.1197293; Lavergne A, Dumont A, Deshayes S, Boutemy J, Maigné G, Silva NM, et al. Efficacy and tolerance of methotrexate in a real-life monocentric cohort of patients with giant cell arteritis. Semin Arthritis Rheum. 2023;60:152192. doi:10.1016/j.semarthrit.2023.152192; Kramarič J, Rotar Ž, Tomšič M, Hočevar A. Performance of leflunomide as a steroid-sparing agent in giant cell arteritis: A single-center, open-label study. Front Med (Lausanne). 2022;9:1069013. doi:10.3389/fmed.2022.1069013; Tomelleri A, Coath F, Sebastian A, Prieto-Pena D, Kayani A, Mo J, et al. Long-term efficacy and safety of leflunomide in large-vessel giant cell arteritis: A single-center, 10-year experience. J Clin Rheumatol. 2022;28(1):e297-e300. doi:10.1097/RHU.0000000000001703; Kreis L, Dejaco C, Schmidt WA, Németh R, Venhoff N, Schäfer VS. The Meteoritics Trial: Efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study. Trials. 2024;25(1):56. doi:10.1186/s13063-024-07905-4; Samson M, Greigert H, Ciudad M, Gerard C, Ghesquière T, Trad M, et al. Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis. Clin Transl Immunology. 2021;10(9):e1332. doi:10.1002/cti2.1332; Matsumoto K, Suzuki K, Takeshita M, Takeuchi T, Kaneko Y. Changes in the molecular profiles of large-vessel vasculitis treated with biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors. Front Immunol. 2023;14:1197342. doi:10.3389/fimmu.2023.1197342; Adriawan IR, Atschekzei F, Dittrich-Breiholz O, Garantziotis P, Hirsch S, Risser LM, et al. Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis. Ann Rheum Dis. 2022;81(1):124-131. doi:10.1136/annrheumdis-2021-220955; O’Neill L, McCormick J, Gao W, Veale DJ, McCarthy GM, Murphy CC, et al. Interleukin-6 does not upregulate pro-inflammatory cytokine expression in an ex vivo model of giant cell arteritis. Rheumatol Adv Pract. 2019;3(1):rkz011. doi:10.1093/rap/rkz011; Rimland CA, Quinn KA, Rosenblum JS, Schwartz MN, Bates Gribbons K, Novakovich E, et al. Outcome measures in large vessel vasculitis: Relationship between patient-, physician-, imaging-, and laboratory-based assessments. Arthritis Care Res (Hoboken). 2020;72(9):1296-1304. doi:10.1002/acr.24117; Berger CT, Rebholz-Chaves B, Recher M, Manigold T, Daikeler T. Serial IL-6 measurements in patients with tocilizumabtreated large-vessel vasculitis detect infections and may predict early relapses. Ann Rheum Dis. 2019;78(7):1012-1014. doi:10.1136/annrheumdis-2018-214704; Samson M, Bonnotte B. Analysis of IL-6 measurement in patients with GCA treated with tocilizumab should consider concomitant treatment with prednisone. Ann Rheum Dis. 2020;79(8):e102. doi:10.1136/annrheumdis-2019-215697; Carvajal Alegria G, Cornec DYK, Renaudineau Y, Saraux A, Devauchelle-Pensec V. Inflammatory markers are quickly improved by tocilizumab in early polymyalgia rheumatica and might predict early response to interleukin-6 blockade. Rheumatol Ther. 2021;8(2):751-760. doi:10.1007/s40744-021-00299-8; Nouri B, Nair N, Barton A. Predicting treatment response to IL6R blockers in rheumatoid arthritis. Rheumatology (Oxford). 2020;59(12):3603-3610. doi:10.1093/rheumatology/keaa529; Redmond C, Zorc R, Sylvester M, Rankin C, Kuan R, Wells K, et al. Impact of IL-6 receptor small nucleotide polymorphism Asp358Ala on T cell activity and clinical outcomes in patients with giant cell arteritis. Arthritis Rheumatol. 2023;75(Suppl 9). URL: https://acrabstracts.org/abstract/impact-of-il-6-receptorsmall-nucleotide-polymorphism-asp358ala-on-t-cell-activityand-clinical-outcomes-in-patients-with-giant-cell-arteritis/ (Accessed: 14th April, 2024).; Kaymakci MS, Warrington KJ, Kermani TA. New therapeutic approaches to large-vessel vasculitis. Annu Rev Med. 2024;75:427-442. doi:10.1146/annurev-med-060622-100940; Springer JM, Kermani TA. Recent advances in the treatment of giant cell arteritis. Best Pract Res Clin Rheumatol. 2023;37(1):101830. doi:10.1016/j.berh.2023.101830; Venhoff N, Schmidt WA, Bergner R, Rech J, Unger L, Tony HP, et al. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol. 2023;5(6):e341-e350. doi:10.1016/S2665-9913(23)00101-7; Cid MC, Unizony SH, Blockmans D, Brouwer E, Dagna L, Dasgupta B, et al.; KPL-301-C001 Investigators. Efficacy and safety of mavrilimumab in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(5):653-661. doi:10.1136/annrheumdis-2021-221865; Conway R, O’Neill L, Gallagher P, McCarthy GM, Murphy CC, Veale DJ, et al. Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial. Semin Arthritis Rheum. 2018;48(3):523-528. doi:10.1016/j.semarthrit.2018.04.004; Matza MA, Fernandes AD, Stone JH, Unizony SH. Ustekinumab for the treatment of giant cell arteritis. Arthritis Care Res (Hoboken). 2021;73(6):893-897. doi:10.1002/acr.24200; Hoffman GS, Cid MC Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al.; Infliximab-GCA Study Group. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: A randomized trial. Ann Intern Med. 2007;146(9):621-630. doi:10.7326/0003-4819-146-9-200705010-00004; Seror R, Baron G, Hachulla E, Debandt M, Larroche C, Puéchal X, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: Results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73(12):2074-2081. doi:10.1136/annrheumdis-2013-203586; Deshayes S, Ly KH, Rieu V, Maigné G, Martin Silva N, Manrique A, et al.; French Study Group for Large Vessel Vasculitis (GEFA). Steroid-sparing effect of anakinra in giant-cell arteritis: A case series with clinical, biological and iconographic long-term assessments. Rheumatology (Oxford). 2021;61(1):400-406. doi:10.1093/rheumatology/keab280; Saraux A, Le Henaff C, Dernis E, Carvajal-Alegria G, Tison A, Quere B, et al. Abatacept in early polymyalgia rheumatica (ALORS): A proof-of-concept, randomised, placebo-controlled, parallel-group trial. Lancet Rheumatol. 2023;5(12):e728-e735. doi:10.1016/S2665-9913(23)00246-1; Rossi D, Cecchi I, Sciascia S, Naretto C, Alpa M, Roccatello D. An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis. Clin Exp Rheumatol. 2021;39 (Suppl 129(2)):125-128. doi:10.55563/clinexprheumatol/l0hd9v; Bolhuis TE, Marsman DE, den Broeder AA, den Broeder N, van der Maas A. 1-year results of treatment with rituximab in polymyalgia rheumatica: An extension study of a randomised double-blind placebo-controlled trial. Lancet Rheumatol. 2023;5(4):e208-e214. doi:10.1016/S2665-9913(23)00032-2; Eriksson P, Skoglund O, Hemgren C, Sjöwall C. Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: A retrospective case series from Sweden. Front Immunol. 2023;14:1187584. doi:10.3389/fimmu.2023.1187584; Zhang L, Li J, Yin H, Chen D, Li Y, Gu L, et al. Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: A phase 2 study. Ann Rheum Dis. 2023;82(5):722-724. doi:10.1136/ard-2022-223562; Насонов ЕЛ, Файст Е. Перспективы ингибиции интерлейкина-6 при ревматоидном артрите: олокизумаб (новые моноклональные антитела к ИЛ-6). Научно-практическая ревматология. 2022;60(5):505-518. doi:10.47360/1995-44842022-505-518

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3600
https://doi.org/10.47360/1995-4484-2024-348-364

Ревматическая полимиалгия в клинических рекомендациях 2018–2020 годов. Часть I. Группы риска, адъювантная терапия

Συγγραφείς: О.G. Puzanovа

Πηγή: Bolʹ, Sustavy, Pozvonočnik, Vol 10, Iss 4, Pp 161-173 (2020)
PAIN, JOINTS, SPINE; Vol. 10 No. 4 (2020); 161-173
Боль. Суставы. Позвоночник-Bolʹ, sustavy, pozvonočnik; Том 10 № 4 (2020); 161-173
Біль. Суглоби. Хребет-Bolʹ, sustavy, pozvonočnik; Том 10 № 4 (2020); 161-173

Θεματικοί όροι: Medicine (General), complications, diagnosis, метотрексат, review, диагностика, лечение, діагностика, polymyalgia rheumatica, обзор, 03 medical and health sciences, R5-920, 0302 clinical medicine, ревматическая полимиалгия, гігантоклітинний артеріїт, осложнения, стандарты, treatment, giant cell arteritis, огляд, ревматична поліміалгія, ускладнення, 3. Good health, гигантоклеточный артериит, лікування, стандарти

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://pjs.zaslavsky.com.ua/article/download/220456/223681
https://doaj.org/article/43be6179e7894a0b9e08f3067be5dfe5
http://pjs.zaslavsky.com.ua/article/view/220456
https://cyberleninka.ru/article/n/polymyalgia-rheumatica-in-the-2018-2020-clinical-guidelines-part-i-at-risk-groups-adjuvant-therapy
http://pjs.zaslavsky.com.ua/article/view/220456

Clinical manifestations and prognosis of giant cell arteritis: A retrospective cohort study ; Клинические проявления и прогноз гигантоклеточного артериита: ретроспективное когортное исследование

Συγγραφείς: E. E. Filatova, N. M. Bulanov, A. D. Meshkov, O. O. Borodin, I. O. Smitienko, E. V. Chachilo, A. A. Nartov, A. L. Filatova, A. V. Naumov, P. I. Novikov, S. V. Moiseev, Е. Е. Филатова, Н. М. Буланов, А. Д. Мешков, О. О. Бородин, И. О. Смитиенко, Е. В. Чачило, А. А. Нартов, А. Л. Филатова, А. В. Наумов, П. И. Новиков, С. В. Моисеев

Πηγή: Rheumatology Science and Practice; Vol 61, No 6 (2023); 735-743 ; Научно-практическая ревматология; Vol 61, No 6 (2023); 735-743 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: иммуносупрессивная терапия, polymyalgia rheumatica, ultrasound, survival, immunosuppressive therapy, ревматическая полимиалгия, УЗДГ, выживаемость

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3473/2333; Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: A systematic review. JAMA. 2016;315(22):2442-2458. doi:10.1001/jama.2016.5444; Weyand CM, Goronzy JJ. Medium-and large-vessel vasculitis. N Engl J Med. 2003;349(2):160-169. doi:10.1056/NEJMra022694; Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371(1):50-57. doi:10.1056/NEJMcp1214825; Мешков АД, Новиков ПИ, Фомин ВВ, Моисеев СВ. Гигантоклеточный артериит: трудности диагностики и методы лечения. Клиническая фармакология и терапия. 2014;23(2):48-54.; Сатыбалдыев АМ. Гигантоклеточный артериит. Часть I. Терминология, классификация, клинические проявления, диагностика. Современная ревматология. 2012;(3):23-27. doi: 14412/1996-7012-2012-741; Nesher G. The diagnosis and classification of giant cell arteritis. J Autoimmun. 2014;48:73-75. doi:10.1016/j.jaut.2014.01.017; Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(3):633-639. doi:10.1002/art.30155; Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: Revisiting the concept of the disease. Rheumatology. 2017;56(4):506-515. doi: 1093/rheumatology/kew273; Wigley RD, Zhang NZ, Zeng QY, Shi CS, Hu DW, Couchman K, et al. Rheumatic diseases in China: ILAR-China study comparing the prevalence of rheumatic symptoms in northern and southern rural populations. J Rheumatol. 1994;21(8):1484-1490.; Smith CA, Fidler WJ, Pinals RS. The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County, Tennessee. Arthritis Rheum Off J Am Coll Rheumatol. 1983;26(10):1214-1219. doi:10.1002/art.1780261007; Мешков АД, Маслянский АЛ, Ткачева ОН, Мазуров ВИ. Лечение гигантоклеточного артериита: современные возможности и перспективы стероид-сберегающей терапии. Терапия. 2023;1(9):78-88. doi:10.18565/therapy.2023.1.78-88; Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology. 1993;100(4):550-555. doi:10.1016/s0161-6420(93)31608-8; Weyand CM, Liao YJ, Goronzy JJ. The immunopathology of giant cell arteritis: Diagnostic and therapeutic implications. J Neuroophthalmol. 2012;32(3):259. doi:10.1097/WNO.0b013e318268aa9b; Kermani TA, Sreih AG, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al.; Vasculitis Clinical Research Consortium. Evaluation of damage in giant cell arteritis. Rheumatology (Oxford). 2018;57(2):322-328. doi:10.1093/rheumatology/kex397; Мухин НА, Мешков АД, Новиков ПИ, Моисеев СВ, Щербакова ВД, Манукова ВА, и др. Гигантоклеточный артериит: клинические проявления и методы ранней диагностики. Клиническая фармакология и терапия. 2015;24(3):79-85.; de Boysson H, Liozon E, Ly KH, Dumont A, Delmas C, Aouba A. The different clinical patterns of giant cell arteritis. Clin Exp Rheumatol. 2019;37(Suppl 117(2)):57-60.; Gajree S, Borooah S, Dhillon N, Goudie C, Smith C, Aspinall P, et al. Temporal artery biopsies in south-east Scotland: A five year review. J R Coll Physicians Edinb. 2017;47(2):124-128. doi:10.4997/JRCPE.2017.203; Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17(5):603-606. doi:10.1007/s10157-013-0869-6; Новиков ПИ, Семенкова ЕН, Моисеев СВ. Современная номенклатура системных васкулитов. Клиническая фармакология и терапия. 2013;22(1):70-74.; Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, et al. Large-vessel involvement in giant cell arteritis: A population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis. 2013;72(12):1989-1994. doi:10.1136/annrheumdis-2012-202408; Breuer GS, Poltorak V, Nesher G. Survival of patients with giant cell arteritis: A controversial issue. Clin Exp Rheumatol. 2020;38(Suppl 124):210-213.; Schmidt J, Smail A, Roche B, Gay P, Salle V, Pellet H, et al. Incidence of severe infections and infection-related mortality during the course of giant cell arteritis: A multicenter, prospective, double-cohort study. Arthritis Rheumatol. 2016;68(6):1477-1482. doi:10.1002/art.39596; Mollan SP, Begaj I, Mackie S, O’Sullivan EP, Denniston AK. Increase in admissions related to giant cell arteritis and polymyalgia rheumatica in the UK, 2002–13, without a decrease in associated sight loss: Potential implications for service provision. Rheumatology. 2015;54(2):375-377. doi:10.1093/rheumatology/keu433; Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122-1128. doi:10.1002/art.1780330810; Salehi-Abari I. 2016 ACR revised criteria for early diagnosis of giant cell (temporal) arteritis. Autoimmune Dis Ther Approaches Open Access. 2016;3:1-4.; Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, et al.; DCVAS Study Group. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis. 2022;81(12):1647-1653. doi:10.1136/ard-2022-223480; Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C. 2012 provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/ American College of Rheumatology collaborative initiative. 2012;64:943-954. doi:10.1002/art.34356; Bland JM, Altman DG. Survival probabilities (the Kaplan – Meier method). BMJ. 1998;317:1572-1580. doi:10.1136/bmj.317.7172.1572; Majerovich K, Junek M, Khalidi N, Garner S. Duration of steroid therapy and temporal artery biopsy positivity in giant cell arteritis: A retrospective cohort study. J Rheumatol. 2023;50(7):965-966. doi:10.3899/jrheum.220860; Dagostin MA, Pereira RMR. Giant cell arteritis: Current advances in pathogenesis and treatment. Rijeka:IntechOpen;2020. doi:10.5772/intechopen.91018; Kermani TA, Warrington KJ. Polymyalgia rheumatica. Lancet. 2013;381(9860):63-72. doi:10.1016/S0140-6736(12)60680-1; Patil P, Williams M, Maw WW, Achilleos K, Elsideeg S, Dejaco C, et al. Fast track pathway reduces sight loss in giant cell arteritis: Results of a longitudinal observational cohort study. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S103-S106.; Ninet JP, Bachet P, Dumontet CM, Du Colombier PB, Stewart MD, Pasquier JH. Subclavian and axillary involvement in temporal arteritis and polymyalgia rheumatica. Am J Med. 1990;88(1):13-20. doi:10.1016/0002-9343(90)90121-s; Berti A, Campochiaro C, Cavalli G, Pepe G, Praderio L, Sabbadini MG, et al. Giant cell arteritis restricted to the limb arteries: An overlooked clinical entity. Autoimmun Rev. 2015;14(4):352-357. doi:10.1016/j.autrev.2014.12.005; Alba MA, García-Martínez A, Prieto-González S, Tavera-Bahillo I, Corbera-Bellalta M, Planas-Rigol E, et al. Relapses in patients with giant cell arteritis: Prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore). 2014;93(5):194-201. doi:10.1097/MD.0000000000000033; Murchison AP, Gilbert ME, Bilyk JR, Eagle RC Jr, Pueyo V, Sergott RC, et al. Validity of the American College of Rheumatology criteria for the diagnosis of giant cell arteritis. Am J Ophthalmol. 2012;154(4):722-729. doi:10.1016/j.ajo.2012.03.045; Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al.; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594-1597. doi:10.1093/rheumatology/keq039a; Moiseev SV, Smitienko I, Bulanov N, Novikov PI. The role of temporal artery biopsy in patients with giant-cell arteritis is debated. Ann Rheum Dis. 2019;78(4):e31. doi:10.1136/annrheumdis-2018-213282; Schäfer VS, Juche A, Ramiro S, Krause A, Schmidt WA. Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis. Rheumatology. 2017;56(9):1479-1483. doi:10.1093/rheumatology/kex143; Филатова ЕЕ, Буланов НМ, Мешков АД, Бородин ОО, Смитиенко ОИ, Чачило ЕВ, и др. Поражение экстракраниальных артерий при гигантоклеточном артериите по данным позитронно-эмиссионной и компьютерной томографии. Научно-практическая ревматология. 2023;61(1):106-111. doi:10.47360/1995-4484-2023-106-111; Henckaerts L, Gheysens O, Vanderschueren S, Goffin K, Blockmans D. Use of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of polymyalgia rheumatica – A prospective study of 99 patients. Rheumatology. 2018;57(11):1908-1916. doi:10.1093/rheumatology/kex376; de Boysson H, Lambert M, Liozon E, Boutemy J, Maigné G, Ollivier Y, et al. Giant-cell arteritis without cranial manifestations: Working diagnosis of a distinct disease pattern. Medicine (Baltimore). 2016;95(26):e3818. doi:10.1097/MD.0000000000003818; Malich L, Gühne F, Hoffmann T, Malich A, Weise T, Oelzner P, et al. Distribution patterns of arterial affection and the influence of glucocorticoids on 18F-fluorodeoxyglucose positron emission tomography/CT in patients with giant cell arteritis. RMD Open. 2022;8(2):e002464. doi:10.1136/rmdopen-2022-002464; Gribbons KB, Ponte C, Carette S, Craven A, Cuthbertson D, Hoffman GS, et al. Patterns of arterial disease in Takayasu arteritis and giant cell arteritis. Arthritis Care Res (Hoboken). 2020;72(11):1615-1624. doi:10.1002/acr.24055; Förster S, Tato F, Weiss M, Czihal M, Rominger A, Bartenstein P, et al. Patterns of extracranial involvement in newly diagnosed giant cell arteritis assessed by physical examination, colour coded duplex sonography and FDG-PET. Vasa. 2011;40(3):219-227. doi:10.1024/0301-1526/a000096; Nielsen BD, Hansen IT, Kramer S, Haraldsen A, Hjorthaug K, Bogsrud TV, et al. Simple dichotomous assessment of cranial artery inflammation by conventional 18F-FDG PET/CT shows high accuracy for the diagnosis of giant cell arteritis: A case-control study. Eur J Nucl Med Mol Imaging. 2019;46(1):184-193. doi:10.1007/s00259-018-4106-0; Rottenburger C, Mensch N, Imfeld S, Aschwanden M, Glatz K, Staub D, et al. 18F-FDG PET/CT compared with ultrasound and biopsy for detection of vasculitis of the temporal artery branches. Swiss Med Wkly. 2021;151:w20512. doi:10.4414/smw.2021.20512; Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19-30. doi:10.1136/annrheumdis-2019-215672; Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021;73(8):1349-1365. doi:10.1002/art.41774; Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL, Dasgupta B. Giant cell arteritis and polymyalgia rheumatica: Current challenges and opportunities. Nat Rev Rheumatol. 2017;13(10):578-592. doi:10.1038/nrrheum.2017.142; Kermani TA, Warrington KJ, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al.; Vasculitis Clinical Research Consortium. Disease relapses among patients with giant cell arteritis: A prospective, longitudinal cohort study. J Rheumatol. 2015;42(7):1213-1217. doi:10.3899/jrheum.141347; Dejaco C, Kerschbaumer A, Aletaha D, Bond M, Hysa E, Camellino D, et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2023:ard-2022-223429. doi:10.1136/ard-2022-223429; Lavergne A, Dumont A, Deshayes S, Boutemy J, Maigné G, Silva NM, et al. Efficacy and tolerance of methotrexate in a reallife monocentric cohort of patients with giant cell arteritis. Semin Arthritis Rheum. 2023;60:152192. doi:10.1016/j.semarthrit.2023.152192; Dumont A, Parienti JJ, Delmas C, Boutemy J, Maigné G, Martin Silva N, et al. Factors associated with relapse and dependence on glucocorticoids in giant cell arteritis. J Rheumatol. 2020;47(1):108-116. doi:10.3899/jrheum.181127; Vautier M, Dupont A, de Boysson H, Comarmond C, Mirault T, Mekinian A, et al. Prognosis of large vessel involvement in large vessel vasculitis. J Autoimmun. 2020;108:102419. doi:10.1016/j.jaut.2020.102419; Catanoso M, Macchioni P, Boiardi L, Muratore F, Restuccia G, Cavazza A, et al. Incidence, prevalence, and survival of biopsy-proven giant cell arteritis in northern Italy during a 26-year period. Arthritis Care Res (Hoboken). 2017;69(3):430-438. doi:10.1002/acr.22942; Garen T, Lerang K, Hoffmann-Vold AM, Andersson H, Midtvedt Ø, Brunborg C, et al. Mortality and causes of death across the systemic connective tissue diseases and the primary systemic vasculitides. Rheumatology (Oxford). 2019;58(2):313-320. doi:10.1093/rheumatology/key285; Hill CL, Black RJ, Nossent JC, Ruediger C, Nguyen L, Ninan JV, Lester S. Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2017;46(4):513-519. doi:10.1016/j.semarthrit.2016.08.015

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3473
https://doi.org/10.47360/1995-4484-2023-735-743

Damage to extracranial arteries in giant cell arteritis according to PET/CT ; Поражение экстракраниальных артерий при гигантоклеточном артериите по данным позитронно-эмиссионной и компьютерной томографии

Συγγραφείς: E. E. Filatova, N. M. Bulanov, A. D. Meshkov, O. O. Borodin, I. O. Smitienko, E. V. Chachilo, P. I. Novikov, S. V. Moiseev, Е. Е. Филатова, Н. М. Буланов, А. Д. Мешков, О. О. Бородин, И. О. Смитиенко, Е. В. Чачило, П. И. Новиков, С. В. Моисеев

Πηγή: Rheumatology Science and Practice; Vol 61, No 1 (2023); 106-111 ; Научно-практическая ревматология; Vol 61, No 1 (2023); 106-111 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: глюкокортикостероиды, 18F-fluorodeoxyglucose-PET/CT, polymyalgia rheumatica, glucocorticosteroids, 18F-фтордезоксиглюкоза-ПЭТ/КТ, ревматическая полимиалгия

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3286/2264; Chew SSL, Kerr NM, Danesh-Meyer HV. Giant cell arteritis. J Clin Neurosci. 2009;16(10):1263-1268. doi:10.1016/j.jocn.2009.05.002; Salvarani C, Crowson CS, O’Fallon WM, Hunder GG, Gabriel SE. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum. 2004;51(2):264-268. doi:10.1002/art.20227; Salvarani С, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372(9634):234-245. doi:10.1016/S0140-6736(08)61077-6; Мешков АД, Лукина ГВ, Новиков ПИ, Федоров КЕ. Головная боль при ревматических заболеваниях. Медицинский алфавит. 2020;(11):22-31. doi:10.33667/2078-5631-2020-11-22-31; Koster MJ, Warrington KJ. Classification of large vessel vasculitis: Can we separate giant cell arteritis from Takayasu arteritis. Presse Med. 2017;46(7-8):205-213. doi:10.1016/j.lpm.2016.11.032; Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: A population-based study. Ann Intern Med. 1995;122(7):502-507. doi:10.7326/0003-4819-122-7-199504010-00004; Koster MJ, Crowson CS, Labarca C, Warrington KJ. Incidence and predictors of thoracic aortic damage in biopsy-proven giant cell arteritis. Scand J Rheumatol. 2021;50(3):239-242. doi:10.1080/03009742.2020.1786855; Филатова ЕЕ, Чачило ЕВ, Буланов НМ, Бородин ОО, Мешков АД, Смитиенко ИО, и др. Гигантоклеточный артериит в сочетании с ревматической полимиалгией: клинические проявления, диагностика и лечение. Клиническая фармакология и терапия. 2022;31(1):75-82. doi:10.32756/0869-5490-2022-1-75-82; Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122-1128. doi:10.1002/art.1780330810; Gotthardt M, Bleeker-Rovers CP, Boerman OC, Oyen WJG. Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med. 2010;51(12):1937-1949. doi:10.2967/jnumed.110.076232; Мешков АД, Новиков ПИ, Фомин ВВ, Моисеев СВ. Гигантоклеточный артериит: трудности диагностики и методы лечения. Клиническая фармакология и терапия. 2014;23(2):48-54.; Grayson PC, Alehashemi S, Bagheri AA, Civelek AC, Cupps TR, Kaplan MJ, et al. 18 F-fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheumatol. 2018;70(3):439-449. doi:10.1002/art.40379; Nielsen BD, Gormsen LC. 18F-fluorodeoxyglucose PET/computed tomography in the diagnosis and monitoring of giant cell arteritis. PET Clin. 2020;15(2):135-145. doi:10.1016/j.cpet.2019.11.007; Besson FL, Parienti JJ, Bienvenu B, Prior JO, Costo S, Bouvard G, et al. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: A systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38(9):1764-1772. doi:10.1007/s00259-011-1830-0; Sait MR, Lepore M, Kwasnicki R, Allington J, Balasubramanian R, Somasundaram SK, et al. The 2016 revised ACR criteria for diagnosis of giant cell arteritis – Our case series: Can this avoid unnecessary temporal artery biopsies? Int J Surg Open. 2017;9:19-23. doi:10.1016/j.ijso.2017.09.003; Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum. 2012;64(4):943-954. doi:10.1002/art.34356; Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Care Res (Hoboken). 2021;73(8):1071-1087. doi:10.1002/acr.24632; Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2 018;77(5):636-643. doi:10.1136/annrheumdis-2017-212649; Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42(2):311-317. doi:10.1002/1529-0131(199902)42:23.0.CO;2-F; Бекетова ТВ, Оттева ЭН, Насонов ЕЛ. Возможности применения тоцилизумаба у больных гигантоклеточным артериитом и ревматической полимиалгией с тяжелой коморбидной патологией: опыт двух российских центров. Клиническая фармакология и терапия. 2020;29(1):31-35. doi:10.32756/0869-5490-2020-1-31-35; Boysson H, Liozon E, Lambert M, Parienti JJ, Boutemy J, Ly K, et al. OP0001 [18F] Fdg PET in giant-cell arteritis: a prognostic tool for aortic complications. Ann Rheum Dis. 2014;73(Suppl 2):60. doi:10.1136/annrheumdis-2014-eular.1985; Blockmans D, de Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: A prospective study of 35 patients. Arthritis Rheum. 2006;55(1):131-137. doi:10.1002/art.21699; Agard C, Barrier JH, Dupas B, Ponge T, Mahr A, Fradet G, et al. Aortic involvement in recent-onset giant cell (temporal) arteritis: A case-control prospective study using helical aortic computed tomodensitometric scan. Arthritis Rheum. 2008;59(5):670-676. doi:10.1002/art.23577; Blockmans D, De Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: A prospective study in 35 patients. Rheumatology (Oxford). 2007;46(4):672-677. doi:10.1093/rheumatology/kel376; Prieto-González S, Arguis P, García-Martínez A, EspígolFrigolé G, Tavera-Bahillo I, Butjosa M, et al. Large vessel involvement in biopsy-proven giant cell arteritis: Prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis. 2012;71(7):1170-1176. doi:10.1136/annrheumdis-2011-200865; Brodmann M, Lipp RW, Passath A, Seinost G, Pabst E, Pilger E. The role of 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of giant cell arteritis of the temporal arteries. Rheumatology (Oxford). 2004;43(2):241-242. doi:10.1093/rheumatology/keh025; Nielsen BD, Hansen IT, Kramer S, Haraldsen A, Hjorthaug K, Bogsrud TV, et al. Simple dichotomous assessment of cranial artery inflammation by conventional 18F-FDG PET/CT shows high accuracy for the diagnosis of giant cell arteritis: A case-control study. Eur J Nucl Med Mol Imaging. 2019;46(1):184-193. doi:10.1007/s00259-018-4106-0; Flaus A, Granjon D, Habouzit V, Gaultier JB, Prevot-Bitot N. Unusual and diffuse hypermetabolism in routine 18F-FDG PET/CT of the supra-aortic vessels in biopsy-positive giant cell arteritis. Clin Nucl Med. 2018;43(9):e336-e337. doi:10.1097/RLU.0000000000002198; Prieto-González S, Depetris M, García-Martínez A, EspígolFrigolé G, Tavera-Bahillo I, Corbera-Bellata M, et al. Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: A prospective, case-control study. Ann Rheum Dis. 2014;73(7):1388-1392. doi:10.1136/annrheumdis-2013-204572; Castellani M, Vadrucci M, Florimonte L, Caronni M, Benti R, Bonara P. 18F-FDG uptake in main arterial branches of patients with large vessel vasculitis: Visual and semiquantitative analysis. Ann Nucl Med. 2016;30(6):409-420. doi:10.1007/s12149-016-1075-x; Loricera J, Blanco R, Hernández JL, Carril JM, Martínez-Rodríguez I, Canga A, et al. Non-infectious aortitis: A report of 32 cases from a single tertiary centre in a 4-year period and literature review. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S19-S31.; de Boysson H, Liozon E, Lambert M, Parienti JJ, Artigues N, Geffray L, et al. 18F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis: A multicenter cohort of 130 patients. Medicine (Baltimore). 2016;95(26):e3851. doi:10.1097/MD.0000000000003851; Hay B, Mariano-Goulart D, Bourdon A, Benkiran M, Vauchot F, De Verbizier D, et al. Diagnostic performance of 18F-FDG PET-CT for large vessel involvement assessment in patients with suspected giant cell arteritis and negative temporal artery biopsy. Ann Nucl Med. 2019;33(7):512-520. doi:10.1007/s12149-019-01358-5; Gribbons KB, Ponte C, Carette S, Craven A, Cuthbertson D, Hoffman GS, et al. Patterns of arterial disease in Takayasu arteritis and giant cell arteritis. Arthritis Care Res (Hoboken). 2020;72(11):1615-1624. doi:10.1002/acr.24055

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3286
https://doi.org/10.47360/1995-4484-2023-106-111

Polymyalgia rheumatica in the 2018–2020 guidelines. Part II: diagnosis of vasculitis

Συγγραφείς: Puzanova, О.H., Lyzikov, А.А.

Πηγή: Bolʹ, Sustavy, Pozvonočnik, Vol 11, Iss 1, Pp 1-16 (2021)
PAIN, JOINTS, SPINE; Vol. 11 No. 1 (2021); 1-16
Боль. Суставы. Позвоночник-Bolʹ, sustavy, pozvonočnik; Том 11 № 1 (2021); 1-16
Біль. Суглоби. Хребет-Bolʹ, sustavy, pozvonočnik; Том 11 № 1 (2021); 1-16

Θεματικοί όροι: Medicine (General), R5-920, ревматическая полимиалгия, гигантоклеточный артериит, аортит, визуализирующая диагностика, стандарты, обзор, ревматична поліміалгія, гігантоклітинний артеріїт, аортит, візуалізуюча діагностика, стандарти, огля, polymyalgia rheumatica, giant-cell arteritis, aortitis, imaging diagnostics, standards, review

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: https://doaj.org/article/8405de28655a4e5d8f2deb95f7a3f962
http://pjs.zaslavsky.com.ua/article/view/226904

Polymyalgia rheumatica: concerted efforts of the European rheumatological societies

Συγγραφείς: Puzanova, О.G., Moshkovska, Yu.О., Sobol, V.О.

Πηγή: Bolʹ, Sustavy, Pozvonočnik, Vol 10, Iss 3, Pp 118-126 (2020)
PAIN, JOINTS, SPINE; Том 10, № 3 (2020); 118-126
Боль. Суставы. Позвоночник-Bolʹ, sustavy, pozvonočnik; Том 10, № 3 (2020); 118-126
Біль. Суглоби. Хребет-Bolʹ, sustavy, pozvonočnik; Том 10, № 3 (2020); 118-126

Θεματικοί όροι: 03 medical and health sciences, Medicine (General), 0302 clinical medicine, R5-920, treatment, polymyalgia rheumatica, standards, review, ревматична поліміалгія, лікування, стандарти, огляд, ревматическая полимиалгия, лечение, стандарты, обзор, 3. Good health

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: https://doaj.org/article/031ebeaa243149779c8ba9d0f98c0d14
http://pjs.zaslavsky.com.ua/article/view/212033

Коморбідні стани в ревматологічній практиці: проблема паранеопластичного синдрому ; Коморбидные состояния в ревматологической практике: проблема паранеопластического синдрома ; The comorbid conditions in rheumatological practice: paraneoplastic syndrome problem

Συγγραφείς: Ждан, Вячеслав Миколайович, Волченко, Григорій Вілійович, Бабаніна, Марина Юріївна, Ткаченко, Максим Васильович, Хайменова, Галина Сергіївна, Ждан, Вячеслав Николаевич, Волченко, Григорий Вилльевич, Бабанина, Марина Юрьевна, Ткаченко, Максим Васильевич, Хайменова, Галина Сергеевна, Zhdan, V. M., Volchenko, H. V., Babanina, M. Yu., Tkachenko, M. V., Khaimenova, H. S.

Θεματικοί όροι: паранеопластичний синдром, ревматологія, гіпертрофічна остеоартропатія, ревматична поліміалгія, пальмарний фасціїт, паранеопластический синдром, ревматология, гипертрофическая остеоартропатия, ревматическая полимиалгия, пальмарный фасциит, paraneoplastic syndrome, rheumatology, hypertrophic osteoarthropathy, polymyalgia rheumatica, palmar fasciitis

Περιγραφή αρχείου: application/pdf

Relation: Коморбідні стани в ревматологічній практиці: проблема паранеопластичного синдрому / В. М. Ждан, Г. В. Волченко, М. Ю. Бабаніна, М. В. Ткаченко, Г. С. Хайменова // Вісник проблем біології і медицини. – 2019. – Вип. 4, т. (153). – С. 26–30.; https://repository.pdmu.edu.ua/handle/123456789/11558

Διαθεσιμότητα: https://repository.pdmu.edu.ua/handle/123456789/11558
https://doi.org/10.29254/2077-4214-2019-4-1-153-26-30

ОБЗОР РЕКОМЕНДАЦИЙ ПО ЛЕЧЕНИЮ РЕВМАТИЧЕСКОЙ ПОЛИМИАЛГИИ (EULAR/ACR 2015)

Συγγραφείς: Н.Т. Ватутин, А.С. Смирнова, Г.Г. Тарадин, М.А. Эль-Хатиб

Θεματικοί όροι: ревматическая полимиалгия, лечение, рекомендации

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/obzor-rekomendatsiy-po-lecheniyu-revmaticheskoy-polimialgii-eular-acr-2015
http://cyberleninka.ru/article_covers/16431745.png

РЕВМАТИЧЕСКАЯ ПОЛИМИАЛГИЯ, ОСЛОЖНИВШАЯСЯ АА-АМИЛОИДОЗОМ

Συγγραφείς: ЗУБКИН МИХАИЛ ЛЕОНИДОВИЧ, ОВЧИННИКОВ Ю.В., ФРОЛОВА Н.Ф., ЧЕРВИНКО В.И., ЗАГРЕБНЕВА А.И., ВОЛОДИНА Е.В., СТОЛЯРЕВИЧ Е.С., ЧУМИКОВ А.А., НОВОЖЕНОВ В.Г., РАДЕНСКА-ЛОПОВОК С.Г.

Θεματικοί όροι: РЕВМАТИЧЕСКАЯ ПОЛИМИАЛГИЯ,ГИГАНТОКЛЕТОЧНЫЙ АРТЕРИИТ,АА-АМИЛОИДОЗ,НЕФРОТИЧЕСКИЙ СИНДРОМ,КОРТИКОСТЕРОИДЫ,RHEUMATIC MYALGIA,GIANT CELL ARTERITIS,AA-AMYLOIDOSIS,NEPHROTIC SYNDROME,CORTICOSTEROIDS

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/revmaticheskaya-polimialgiya-oslozhnivshayasya-aa-amiloidozom
http://cyberleninka.ru/article_covers/16446364.png

Случай ревматической полимиалгии

Συγγραφείς: Барт, Б., Кудина, Е., Ларина, Вера

Θεματικοί όροι: РЕВМАТИЧЕСКАЯ ПОЛИМИАЛГИЯ, ПОЖИЛОЙ ВОЗРАСТ, МИАЛГИЯ, ПРЕДНИЗОЛОН, СИНОВИИТ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/sluchay-revmaticheskoy-polimialgii
http://cyberleninka.ru/article_covers/15804479.png

УЛЬТРАЗВУКОВЫЕ ПРОЯВЛЕНИЯ РЕВМАТИЧЕСКОЙ ПОЛИМИАЛГИИ

Συγγραφείς: Кириллова, Э.

Θεματικοί όροι: РЕВМАТИЧЕСКАЯ ПОЛИМИАЛГИЯ, УЛЬТРАЗВУКОВОЕ ИССЛЕДОВАНИЕ, ПЛЕЧЕВОЙ СУСТАВ, ТАЗОБЕДРЕННЫЙ СУСТАВ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/ultrazvukovye-proyavleniya-revmaticheskoy-polimialgii
http://cyberleninka.ru/article_covers/15815957.png

Обзор рекомендаций по лечению ревматической полимиалгии (EULAR/ACR 2015)

Πηγή: Архивъ внутренней медицины.

Θεματικοί όροι: ревматическая полимиалгия, лечение, рекомендации, 3. Good health

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article/n/obzor-rekomendatsiy-po-lecheniyu-revmaticheskoy-polimialgii-eular-acr-2015
http://cyberleninka.ru/article_covers/16431745.png

ЛЕЧЕНИЕ РЕВМАТИЧЕСКОЙ ПОЛИМИАЛГИИ

Συγγραφείς: Сатыбалдыев, Азамат

Θεματικοί όροι: РЕВМАТИЧЕСКАЯ ПОЛИМИАЛГИЯ, ГЛЮКОКОРТИКОИДЫ, ПРЕДНИЗОН, ПРЕДНИЗОЛОН, МЕТИЛПРЕДНИЗОЛОН, ДЕФЛАЗАКОРТ, МЕТОТРЕКСАТ, АЗАТИОПРИН, НЕСТЕРОИДНЫЕ ПРОТИВОВОСПАЛИТЕЛЬНЫЕ ПРЕПАРАТЫ, БИОЛОГИЧЕСКАЯ ТЕРАПИЯ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/lechenie-revmaticheskoy-polimialgii
http://cyberleninka.ru/article_covers/14431299.png

МИАЛГИИ: ПОДХОДЫ К ДИФФЕРЕНЦИАЛЬНОЙ ДИАГНОСТИКЕ, ЛЕЧЕНИЕ

Συγγραφείς: Шостак, Надежда

Θεματικοί όροι: МИАЛГИИ, МИОФАСЦИАЛЬНЫЙ СИНДРОМ, ФИБРОМИАЛГИЯ, РЕВМАТИЧЕСКАЯ ПОЛИМИАЛГИЯ, ДИФФЕРЕНЦИАЛЬНАЯ ДИАГНОСТИКА, ЛЕЧЕНИЕ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/mialgii-podhody-k-differentsialnoy-diagnostike-lechenie
http://cyberleninka.ru/article_covers/14492457.png

СЛУЧАЙ БОЛЕЗНИ ХОРТОНА В ПРАКТИКЕ ВРАЧА-ТЕРАПЕВТА

Συγγραφείς: Кузнецова, Юлия, Крохина, Елена

Θεματικοί όροι: БОЛЕЗНЬ ХОРТОНА, ВАСКУЛИТ, РЕВМАТИЧЕСКАЯ ПОЛИМИАЛГИЯ, HORTON'S ILLNESS

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/sluchay-bolezni-hortona-v-praktike-vracha-terapevta
http://cyberleninka.ru/article_covers/14040190.png

CURRENT VIEW OF HORTON'S DISEASE: ANALYSIS OF ITS CASES IN THE KHABAROVSK TERRITORY ; СОВРЕМЕННЫЙ ВЗГЛЯД НА БОЛЕЗНЬ ХОРТОНА: АНАЛИЗ СЛУЧАЕВ В ХАБАРОВСКОМ КРАЕ

Συγγραφείς: E. N. Otteva, T. Yu. Kocherova, Э. Н. Оттева, Т. Ю. Кочерова

Πηγή: Rheumatology Science and Practice; Vol 49, No 5 (2011); 38-45 ; Научно-практическая ревматология; Vol 49, No 5 (2011); 38-45 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2011-3

Θεματικοί όροι: глюкокортикоидная терапия, polymyalgia rheumatica, diagnostic criteria, clucocorticoid therapy, ревматическая полимиалгия, диагностические критерии

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1291/1032; Бунчук Н.В. Ревматические заболевания пожилых. М.: МЕДпрессинформ, 2010; с. 6-136 Насонов Е.Л., Баранов А.А., Шиллкина Н.П. Васкулиты и васкулопатии. Ярославль: Верхняя Волга, 1999; 614 с Ревматология: Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008;714 с. Horton B.T., Magath T.B., Brown G.E. An undescribed form of arteritis of the temporal vessels. Mayo Clin Proc 1932;7:700-1. Weyand C.M., Goronzy J.J. Arterial wall injury in giant cell arteritis. Arthr Rheum 1999;42:844-53. Weyand C.M., Goronzy J.J. Mediumand large-vessel vasculitis. N Engl J Med 2003;349:160-9. Evans J.M., Hunder G.G. Polymyalgia rheumatica and giant cell arteritis. Rheum Dis Clin North Am 2000;26:493-515. Uddhammar A., Eriksson A.L., Nystrom L. et al. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 2002;29:737-42. Franzеn P., Sutinen S., von Knorring J. Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984-1988. J Rheumatol 1992;19:273-6. Hunder G.G. Epidemiology of giant cell arterits. Cleve Clin J Med 2002;69(Suppl. 2):S1179-S1182 Lawrence R.C., Helmick C.G., Arnett F.C. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthr Rheum 1998;41:778-99. Machado E.B., Michet C.J., Ballard D.J. et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950-1985. Arthr Rheum 1988;31:745-9. Gay M.A., Alonso M.D., Aguero J.J. et al. Temporal arteritis in a northwestern area of Spain: study of 57 biopsy proven patients. J Rheumatol 1992;19:277-80. Smeeth L., Cook C., Hall A.J. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990 to 2001. Ann Rheum Dis 2006;65:1093-8. Dababneh A., Gonzalez-Gay M.A., Garcia-Porrua C. et al. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol 1998;25:2140-5. Wagner A.D., Bjornsson J., Bartley G.B. et al. Interferon-gamma-producing T cells in giant cell vasculitis represent a minority of tissue infiltrating cells and are located distant from the site of pathology. Am J Pathol 1996;148:1925-33. Weyand C.M., Hicok K.C., Hunder G.G., Goronzy J.J. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest 1992;90:2355-61. Weyand C.M., Hunder N.N., Hicok K.C. et al. Comparison of polymyalgia rheumatica, giant cell arteritis and rheumatoid arthritis by genetic linkage analysis. Arthr Rheum 1994;37:514-20 Weyand C.M., Hicok K.C., Hunder G.G., Goronzy J.J. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994;121:484-91 Weyand C.M., Tetzlaff N., Bjornsson J. et al. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthr Rheum 1997;40:19-26. Weyand C.M., Goronzy J.J. Giant-Cell Arteritis and Polymyalgia Rheumatica. Ann Inter Med 2003;139:505-15 Hunder G.G., Valente R.M. Giant cell arteritis: Clinical aspects. In: Hoffman G.S., Weyand C.M., eds. Inflammatory Diseases of Blood Vessels. New York: Marcel Dekker, 2002;425-41. Hunder G.G., Bloch D.A., Michel B.A. et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthr Rheum 1990;33:1122-8. Leeb B.F., Bird H.A. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 2004;63(10):1279-83. Leeb B.F., Bird H.A., Nesher G. et al. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European collaborating Polymyalgia Rheumatica group (subcommittee of ESCISIT). Ann Rheum Dis 2003;62:1189-94. Leeb B.F., Rintelen B., Sautner J. The Polymyalgia Rheumatica Activity Score in Daily Use: Proposal for a Definition of Remission. Arthr Rheum (Arthr Care Res) 2007;57(5):810-5. Leeb B.F. Disease activity assessment in polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) [abstract]. Rheumatology (Oxford) 2005;44 (Suppl. 3): 5-6. Achkar A.A., Hunder G.G., Gabriel S.E. Effect of previous corticosteroid treatment on temporal artery biopsy results [Letter]. Ann Intern Med 1998;128:410 Brack A., Martinez-Taboada V., Stanson A. et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthr Rheum 1999;42:311-7. Ghanchi F.D., Dutton G.N. Current concepts in giant cell (temporal) arteritis. Surv Ophthalmol 1997;42:99-123. Nesher G., Nesher R., Rozenman Y., Sonnenblick M. Visual hallucinations in giant cell arteritis: association with visual loss. J Rheumatol 2001;28:2046-8. Liu G.T., Glaser J.S., Schatz N.J., Smith J.L. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology 1994;101:1779-85. Levine S.M., Hellmann D.B. Giant cell arteritis. Curr Opin Rheumatol 2002;14:3-10 Tovilla-Canales J.L. Ocular manifestations of giant cell arteritis. Curr Opin Ophthalmol 1998;9:73-9. Evans J.M., O'Fallon W.M., Hunder G.G. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995;122:502-7 Evans J.M., Bowles C.A., Bjornsson J. et al. Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthr Rheum 1994;37: 1539-47 Salvarani C., Cantini F., Boiardi L., Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis [review]. N Engl J Med 2002;347:261-71. Weyand C.M., Goronzy J.J. Arterial wall injury in giant cell arteritis. Arthr Rheum 1999;42:844-53. Cantini F., Salvarani C., Olivieri I. et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case control study. J Rheumatol 2001;28:1049-55. Nordborg E., Nordborg C., Bengtsson B.A. Giant cell arteritis. Curr Opin Rheumatol 1992;4:23-30 Cantini F., Salvarani C., Olivieri I. et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthr Rheum 2000;30:17-24. Jones J.G., Hazleman B.L. ESR in polymyalgia rheumatica and giant cell arteritis [Letter]. Ann Rheum Dis 1983;42:702-3. Martinez-Taboada V.M. Giant cell arteritis with an erythrocyte sediemtation rate lower than 50. Clin Rheumatol 2000;19:73-5. Salvarani C., Hunder G.G. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a populationbased study. Arthr Rheum 2001;45:140-5. Seo Ph., Stone J. Large-Vessel Vasculitis. Arthr Rheum 2004;15:128-39. Gonzales-Gay M.A., Garcia-Porrua C., Vazquez-Caruncho M. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheumatol 1998;25:1750-5. Genereau T., Lortholary O., Pottier M.A. et al. Temporal artery biopsy: a diagnostic tool for systemic necrotizing vasculitis. French Vasculitis Study Group. Arthr Rheum 1999;42:2674-81. Foroozan R., Danesh-Meyer H., Savino P.J. Thrombocytosis in patients with biopsy-proven giant cell arteritis. Ophthalmology 2002;109:1267-71 Lie J.T. Temporal artery biopsy diagnosis of giant cell arteritis: lessons from 1109 biopsies. Anat Pathol 1996;1:69-97. Duhaut P., Pinede L., Bornet H. et al. Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Ann Rheum Dis 1999;58:335-41 Allison M., Gallagher P. Temporal artery biopsy and corticosteroid treatment. Ann Rhem Dis 1984;43:416-7 Schmidt W.A., Gromnica-Ihle E. Incidence of temporal arteritis in patients with polymyalgia rheumatica: a prospective study using colour Doppler ultrasonography of the temporal arteries. Rheumatology 2002;4:46-52. Schmidt W.A. Doppler ultrasonography in the diagnosis of giant cell arteritis. Clin Exp Rheumatol 2000;18(Suppl. 20):40-2. Birkhead N.C., Wagener H.P., Schick R.M. Treatment of temporal arteritis with adrenal corticosteroids: Results in 55 cases in which lesion was proven at biopsy. JAMA 1957;163:821-7 Myklebust G., Gran J.T. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective twoyear study in 273 patients. Scand J Rheumatol 2001;30:260-7. Jover J.A., Hernandez-Garcia C., Morado I.C. et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:106-14. Krall P.L., Mazanec D.J., Wilke W.S. Methotrexate for corticosteroidresistant polymyalgia rheumatica and giant cell arteritis. Cleve Clin J Med 1989;56:253-7. Spiera R.F., Mitnick H.J., Kupersmith M. et al. A prospective, doubleblind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001;19:495-501. Weyand C.M., Kaiser M., Yang H. et al. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthr Rheum 2002;46:457-66. Weyand C.M., Fulbright J.W., Hunder G.G. et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthr Rheum 2000;43:1041-8. Hagihara K., Kawase I., Tanaka T., Kishimoto Т. Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica. J Rhematol 2010;37(5):1075-6.

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/1291
https://doi.org/10.14412/1995-4484-2011-1459

СОВРЕМЕННЫЙ ВЗГЛЯД НА БОЛЕЗНЬ ХОРТОНА: АНАЛИЗ СЛУЧАЕВ В ХАБАРОВСКОМ КРАЕ

Συγγραφείς: Оттева, Эльвира, Кочерова, Т.

Θεματικοί όροι: ГИГАНТОКЛЕТОЧНЫЙ АРТЕРИИТ,РЕВМАТИЧЕСКАЯ ПОЛИМИАЛГИЯ,ДИАГНОСТИЧЕСКИЕ КРИТЕРИИ,ГЛЮКОКОРТИКОИДНАЯ ТЕРАПИЯ,GIANT CELL ARTERITIS,POLYMYALGIA RHEUMATICA,DIAGNOSTIC CRITERIA,CLUCOCORTICOID THERAPY

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/sovremennyy-vzglyad-na-bolezn-hortona-analiz-sluchaev-v-habarovskom-krae
http://cyberleninka.ru/article_covers/14491290.png

Случай ревматической полимиалгии

Πηγή: Клиническая медицина.

Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, РЕВМАТИЧЕСКАЯ ПОЛИМИАЛГИЯ, ПОЖИЛОЙ ВОЗРАСТ, МИАЛГИЯ, ПРЕДНИЗОЛОН, СИНОВИИТ, 3. Good health

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article/n/sluchay-revmaticheskoy-polimialgii
http://cyberleninka.ru/article_covers/15804479.png

Ревматическая полимиалгия, осложнившаяся АА-амилоидозом

Πηγή: Клиническая медицина.

Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, РЕВМАТИЧЕСКАЯ ПОЛИМИАЛГИЯ,ГИГАНТОКЛЕТОЧНЫЙ АРТЕРИИТ,АА-АМИЛОИДОЗ,НЕФРОТИЧЕСКИЙ СИНДРОМ,КОРТИКОСТЕРОИДЫ,RHEUMATIC MYALGIA,GIANT CELL ARTERITIS,AA-AMYLOIDOSIS,NEPHROTIC SYNDROME,CORTICOSTEROIDS, 3. Good health

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article/n/revmaticheskaya-polimialgiya-oslozhnivshayasya-aa-amiloidozom
http://cyberleninka.ru/article_covers/16446364.png

Ультразвуковые проявления ревматической полимиалгии

Πηγή: Практическая медицина.

Θεματικοί όροι: РЕВМАТИЧЕСКАЯ ПОЛИМИАЛГИЯ, УЛЬТРАЗВУКОВОЕ ИССЛЕДОВАНИЕ, ПЛЕЧЕВОЙ СУСТАВ, ТАЗОБЕДРЕННЫЙ СУСТАВ, 3. Good health

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article/n/ultrazvukovye-proyavleniya-revmaticheskoy-polimialgii
http://cyberleninka.ru/article_covers/15815957.png